How much has 10x Genomics raised?
10x Genomics is a public company (Nasdaq: TXG), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- Nasdaq: TXG
- First raised
- 2012
- Notable backer
- Public shareholders
10x Genomics's funding rounds
10x Genomics's capital path moved from founding and growth capital into public-company financing.
- 2012Founded10x Genomics is founded to build high-resolution biology tools.
- 2015Chromium launchThe company launches the Chromium single-cell platform.
- 2019IPO10x Genomics lists on Nasdaq under TXG.
- 2023Spatial portfolio expansionXenium and Visium broaden spatial biology exposure.
- 20262025 results10x reports $642.8M of 2025 revenue including patent-settlement revenue.
Sources:10x Genomics FY 2025 results10x Genomics investor relations
How much has 10x Genomics raised in total?
10x Genomics is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are 10x Genomics's investors?
The relevant investor base is the public shareholder base behind Nasdaq: TXG. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. 10x Genomics's latest public materials emphasize $642.8M 2025 revenue; $598.7M excluding patent-settlement revenue, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is 10x Genomics profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does 10x Genomics's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. 10x Genomics can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:10x Genomics FY 2025 results10x Genomics investor relations
10x Genomics — frequently asked questions
